Neurology | Phase I Developments | SWITZERLAND

Idorsia Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Neurocrine Biosciences exercises option to license Idorsia's novel treatment for rare pediatric epilepsy

Lead Product(s): ACT-709478

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Neurocrine Biosciences

Deal Size: $410.0 million Upfront Cash: $45.0 million

Deal Type: Licensing Agreement May 11, 2020

Details:

Neurocrine Biosciences to develop and commercialize ACT-709478, a clinical stage selective T-type calcium channel blocker for the treatment of a rare pediatric epilepsy.

AC Immune

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

AC Immune Receives Second Milestone and New Milestone to Increase the Potential Deal Value of Lilly Morphomer™ Tau Partnership

Lead Product(s): ACI-3024

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Eli Lilly

Deal Size: $105.1 million Upfront Cash: Undisclosed

Deal Type: Collaboration March 23, 2020

Details:

The collaboration combines AC Immune’s proprietary Morphomer discovery platform technology and early development experience with Lilly’s clinical development expertise and commercial capabilities.

Idorsia Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Neurocrine Biosciences and Idorsia Amend Option Agreement to License Novel Treatment for Rare Pediatric Epilepsy

Lead Product(s): ACT-709478

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Neurocrine Biosciences

Deal Size: $417.0 million Upfront Cash: $45.0 million

Deal Type: Licensing Agreement January 10, 2020

Details:

Under this agreement, Neurocrine Biosciences owns option to exclusively license ACT-709478, a clinical stage selective T-type calcium channel blocker for the treatment of epilepsy.

Find

Find Neurology Drugs in Phase I Clinical Development in SWITZERLAND

Switzerland

Product Type

Companies

Idorsia Pharmaceuticals

Neurocrine Biosciences exercises option to license Idorsia's novel treatment for rare pediatric epilepsy

AC Immune

AC Immune Receives Second Milestone and New Milestone to Increase the Potential Deal Value of Lilly Morphomer™ Tau Partnership

Idorsia Pharmaceuticals

Neurocrine Biosciences and Idorsia Amend Option Agreement to License Novel Treatment for Rare Pediatric Epilepsy